VARIABLES |
BRITISH PATIENTS AGE / Years (%) (20-34) (35-49) (50-64) (= / > 65) |
Total | P Value | |||
---|---|---|---|---|---|---|
STAGE | 9 (1.5)* | 101 (16.6) | 242 (39.9) | 255 (42) | 607 | - |
I | 2 (22.2)** | 45 (44.6) | 153 (63.2) | 169 (66.3) | 369 | < .00001 |
II | 3 (33.3) | 53 (52.5) | 82 (33.9) | 82 (32.2) | 220 | |
III | 3 (33.3) | 2 (1.9) | 6 (2.5) | 3 (1.2) | 14 | |
IV | 1 (11.1) | 1 (0.9) | 1 (0.4) | 1 (0.4) | 4 | |
TUMOR SIZE | 17 (1.5) | 203 (17.8) | 431 (37.7) | 493 (43.1) | 1144 | - |
T1 | 5 (29.4) | 110 (54.2) | 291 (67.5) | 317 (64.3) | 723 | 0.00001 |
T2 | 7 (41.2) | 84 (41.4) | 125 (29) | 153 (31) | 369 | |
T3 | 4 (23.5) | 7 (3.4) | 12 (2.8) | 17 (3.4) | 40 | |
T4 | 1 (5.9) | 2 (1.0) | 3 (0.7) | 6 (1.2) | 12 | |
 LYMPH NODE | 15 (1.4) | 198 (18.1) | 417 (38.1) | 465 (42.5) | 1,095 | - |
N0 | 7 (46.7) | 137 (69.2) | 321 (77) | 377 (81.1) | 842 | 0.0008 |
N1 | 5 (33.3) | 55 (27.8) | 82 (19.7) | 72 (15.5) | 214 | |
N2 | 2 (13.3) | 4 (2.0) | 9 (2.2) | 10 (2.2) | 25 | |
N3 | 1 (6.7) | 2 (1.0) | 5 (1.2) | 6 (1.3) | 14 | |
ER STATUS | 15 (1.2) | 215 (16.9) | 487 (38.3) | 555 (43.6) | 1272 | - |
ER Positive | 12 (80) | 180 (83.7) | 425 (87.3) | 483 (87) | 1100 | 0.5049 |
ER Negative | 3 (20) | 35 (16.3) | 62 (12.7) | 72 (13) | 172 | |
PR STATUS | 7 (1.3) | 100 (18.4) | 197 (36.3) | 239 (44) | 543 | - |
PR Positive | 6 (85.7) | 82 (82) | 159 (80.7) | 186 (77.8) | 433 | 0 .7701 |
PR Negative | 1 (14.3) | 18 (18) | 38 (19.3) | 53 (22.2) | 110 | |
HER2 STATUS | 14 (1.2) | 192 (16.9) | 440 (38.7) | 492 (43.2) | 1138 | - |
HER2 Positive | 5 (35.7) | 44 (22.9) | 56 (12.7) | 38 (7.7) | 143 | < .00001 |
HER2 Negative | 9 (64.3) | 148 (77.1) | 384 (87.3) | 454 (92.3) | 995 | |
SUBTYPES | 7 (1.8) | 73 (18.8) | 144 (37) | 165 (42.4) | 389 | - |
Luminal A | 4 (57.1) | 54 (74) | 124 (86.1) | 143 (86.7) | 325 | 0.0681 |
Luminal B | 1 (14.3) | 11 (15.1) | 11 (7.6) | 8 (4.8) | 31 | |
HER2 Enriched | 1 (14.3) | 3 (4.1) | 4 (2.8) | 3 (1.8) | 11 | |
Triple Negative | 1 (14.3) | 5 (6.8) | 5 (3.5) | 11 (6.7) | 22 |